The Investor
23 Sep 2026, 18:21
Johnson & Johnson Highlights Strong Long-Term Survival Potential for TECVAYLI-DARZALEX Combination
Johnson & Johnson reported new MajesTEC-3 analyses suggesting that TECVAYLI plus DARZALEX FASPRO could materially improve long-term outcomes for patients with relapsed or refractory multiple myeloma treated as early as second line.
A model-based analysis estimated that about 87% of patients receiving the combination could eventually have a mortality risk similar to an age-matched general population. Projected remaining life expectancy was 18.5 years with TECVAYLI-DARZALEX versus 4.9 years with the standard-of-care comparator, approaching 21.1 years for the matched general population.
A separate analysis showed that the combination reduced the risk of disease progression by 90% versus standard care. At 36 months, progression had occurred in 8.7% of patients receiving TECVAYLI-DARZALEX compared with 62.1% in the control group. Overall survival at three years was 83.3% versus 65.0%, while non-relapse mortality was not significantly different between the groups.
The findings build on the Phase 3 MajesTEC-3 trial, which evaluates the combination in patients who had received one to three prior therapies. Johnson & Johnson said continued follow-up will be needed to determine whether the model-based long-term survival projections are borne out over time.
The data strengthen the case for moving TECVAYLI earlier in the multiple myeloma treatment pathway and reinforce Johnson & Johnson’s broader strategy of combining bispecific antibodies with established myeloma therapies.
Johnson & Johnson reported new MajesTEC-3 analyses suggesting that TECVAYLI plus DARZALEX FASPRO could materially improve long-term outcomes for patients with relapsed or refractory multiple myeloma treated as early as second line.
A model-based analysis estimated that about 87% of patients receiving the combination could eventually have a mortality risk similar to an age-matched general population. Projected remaining life expectancy was 18.5 years with TECVAYLI-DARZALEX versus 4.9 years with the standard-of-care comparator, approaching 21.1 years for the matched general population.
A separate analysis showed that the combination reduced the risk of disease progression by 90% versus standard care. At 36 months, progression had occurred in 8.7% of patients receiving TECVAYLI-DARZALEX compared with 62.1% in the control group. Overall survival at three years was 83.3% versus 65.0%, while non-relapse mortality was not significantly different between the groups.
The findings build on the Phase 3 MajesTEC-3 trial, which evaluates the combination in patients who had received one to three prior therapies. Johnson & Johnson said continued follow-up will be needed to determine whether the model-based long-term survival projections are borne out over time.
The data strengthen the case for moving TECVAYLI earlier in the multiple myeloma treatment pathway and reinforce Johnson & Johnson’s broader strategy of combining bispecific antibodies with established myeloma therapies.
